n(6)-carboxymethyllysine has been researched along with metformin in 5 studies
| Studies (n(6)-carboxymethyllysine) | Trials (n(6)-carboxymethyllysine) | Recent Studies (post-2010) (n(6)-carboxymethyllysine) | Studies (metformin) | Trials (metformin) | Recent Studies (post-2010) (metformin) |
|---|---|---|---|---|---|
| 803 | 44 | 365 | 17,793 | 3,176 | 12,526 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Machado, AP; Moysés, ZP; Nakandakare, ER; Passarelli, M; Pinto, RS; Quintão, EC | 1 |
| Chang, T; Desai, K; Jia, X; Wang, X; Wu, L | 1 |
| Chen, SM; Huang, TC; Lee, JA; Li, YC | 1 |
| Poretsky, L; Striker, GE; Vlassara, H; Woodward, M; Yubero-Serrano, EM | 1 |
| Berriche, O; Bouzidi, H; Haddad, M; Hammami, M; Kerkeni, M; Knani, I | 1 |
1 trial(s) available for n(6)-carboxymethyllysine and metformin
| Article | Year |
|---|---|
Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease.
Topics: Adiponectin; Age Factors; Aged; Albuminuria; Chelating Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Estrogen Receptor alpha; Female; Glycated Hemoglobin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Lysine; Male; Metformin; Middle Aged; NF-E2-Related Factor 2; Pyruvaldehyde; Receptor for Advanced Glycation End Products; Receptors, Tumor Necrosis Factor, Type I; RNA, Messenger; Sevelamer; Sex Factors; Single-Blind Method; Sirtuin 1; White People | 2015 |
4 other study(ies) available for n(6)-carboxymethyllysine and metformin
| Article | Year |
|---|---|
Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products.
Topics: Albumins; Animals; Atherosclerosis; Cells, Cultured; Cholesterol, HDL; Diabetes Mellitus; Enzyme Inhibitors; Glycation End Products, Advanced; Guanidines; Humans; Hypoglycemic Agents; Lysine; Macrophages, Peritoneal; Metformin; Mice | 2006 |
Attenuation of hypertension development by scavenging methylglyoxal in fructose-treated rats.
Topics: Animals; Aorta; Dietary Carbohydrates; Fructose; Glutathione; Glycation End Products, Advanced; Hydrogen Peroxide; Hypertension; Hypoglycemic Agents; Lysine; Male; Mesenteric Arteries; Metformin; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Pyruvaldehyde; Rats; Rats, Sprague-Dawley | 2008 |
Increased renal semicarbazide-sensitive amine oxidase activity and methylglyoxal levels in aristolochic acid-induced nephrotoxicity.
Topics: Amine Oxidase (Copper-Containing); Animals; Aristolochic Acids; Dose-Response Relationship, Drug; Kidney; Kidney Diseases; Lysine; Male; Metformin; Mice; Mice, Inbred C57BL; Pyruvaldehyde | 2014 |
Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect.
Topics: Adult; Arginine; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Lysine; Male; Metabolic Syndrome; Metformin; Middle Aged; Prognosis; Receptor for Advanced Glycation End Products | 2016 |